Search the Newsreel

Artivion (AORT) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chairman, President, and Chief Executive Officer - Pat MackinExecutive Vice President, Chief Operating Officer and Chief Financial Officer - Lance Berry TAKEAWAYS Revenue -- $125.8 million, up 9% …

5 Revealing Analyst Questions From Artivion’s Q2 Earnings Call

Artivion SVP Jean Holloway sells 977 shares for $27,834

Jean F. Holloway, SVP at Artivion Inc. (NASDAQ:AORT), sold 977 shares for $27,834 at $28.49 per share. This transaction occurred after the stock saw a 9.4% gain over the past week, and Holloway now directly holds 184,118 shares. The company recently reported strong Q2 …

Jean Holloway Sells 977 Shares of Artivion (NYSE:AORT) Stock

Jean Holloway, SVP of Artivion (NYSE:AORT), sold 977 shares of the company's stock for a total of $27,834.73, reducing her direct ownership to 184,118 shares. This transaction occurred as Artivion reported strong quarterly earnings, exceeding revenue estimates, and maintains a "Moderate Buy" consensus rating …

Artivion (AORT) Is Up 5.5% After FDA AMDS Approval And Reaffirmed 2026 Revenue Guidance - What's Changed

Artivion (AORT) stock rose by 5.5% following FDA approval for its AMDS hybrid prosthesis and the reaffirmation of its 2026 revenue guidance. The company reported increased revenue but a shift to a net loss in Q2 2026. This approval for AMDS is considered a …

Artivion, Inc. (AORT) Stock Analysis: Strong Buy Ratings Signal Potential Upside of Nearly 60%

Artivion, Inc. (AORT), a healthcare sector player specializing in medical devices and implantable human tissues, shows promising growth potential despite recent market fluctuations. Analysts have given it strong "Buy" ratings with an average target price of $42.03, suggesting a nearly 60% upside from its …

Artivion (AORT) Revenue Rose As Losses Emerged, Is It Still 37% Below Fair Value?

Artivion (AORT) recently reported Q2 2026 results showing increased revenue but a shift to losses. Despite a year-to-date share price decline, the company's valuation narrative suggests it is 37.4% undervalued, with a fair value of $42. This undervaluation hinges on continued regulatory approvals, new …

Artivion revenue up 11% to USD 125.8M in Q2 2026

Artivion, Inc. reported an 11% increase in total revenues to $125.8 million for Q2 2026, driven by strong growth in On-X and stent grafts. The company also announced the acquisition of Endospan Ltd. and U.S. FDA approval for its AMDS Hybrid Prosthesis, strengthening its …

Artivion (AORT) Stock Can Revenue Growth Outrun Fresh Losses?

Artivion (AORT) saw its stock edge up slightly despite a mixed Q2 2026 earnings report, which showed strong revenue growth but a swing back to a net loss. The company's aortic franchise, particularly with AMDS approval and growth in On X valves, fuels the …

Canaccord raises Artivion stock price target on acquisition, PMA approval

Canaccord raised its price target for Artivion Inc. (NYSE:AORT) to $39 from $36, maintaining a Buy rating, following the company's acquisition of Endospan and PMA approval for AMDS. Artivion's second-quarter revenue of $125.8 million and adjusted EBITDA of $26.4 million both surpassed analyst estimates, …

Long-Term Growth Opportunities Remain for Artivion (AORT) Despite Challenges

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 …

Artivion Q2 Earnings Call Highlights

Key Points Interested in Artivion, Inc.? Here are five stocks we like better. Artivion's Q2 revenue rose 9% to $125.8 million on a constant-currency basis, driven by 12% growth in stent grafts and 18% growth in On-X valves. Adjusted EBITDA increased 7% to $26.4 …

Artivion, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:AORT) 2026-08-07

Artivion, Inc. (AORT) released its 2026 Q2 earnings call presentation. The company reported an EPS of $0.13, beating estimates by $0.03, and revenue of $125.76 million, an 11.32% year-over-year increase, beating estimates by $5.74 million. This article provides access to the slide deck published …

Is Artivion Inc (AORT) Undervalued Despite $125.8 Million Revenue in Q2? GF Score: 82/100

Artivion Inc (AORT) reported Q2 2026 revenues of $125.8 million, an 11% year-over-year increase, exceeding analyst estimates, yet posted a net loss of $13.5 million. Despite the loss, driven partly by foreign currency revaluation and increased operating expenses, the company strengthened its product portfolio …

Earnings call transcript: Artivion tops Q2 2026 revenue forecast as shares rise

Earnings Flash (AORT) Artivion, Inc. Posts Q2 Adjusted EPS $0.13 per Share, Vs. FactSet Est of $0.10

Artivion, Inc. (AORT) announced its Q2 adjusted EPS of $0.13 per share, surpassing the FactSet estimate of $0.10. This indicates a stronger financial performance than anticipated by analysts.

Artivion (AORT) Q2 Earnings Meet Estimates

Artivion (AORT) reported Q2 earnings of $0.13 per share, meeting the Zacks Consensus Estimate, though this is down from $0.24 a year ago. The company's revenues for the quarter were $125.76 million, surpassing estimates by 4.02%. Artivion's stock has underperformed the S&P 500 this …

Artivion Q2 2026 slides: FDA wins fuel aortic arch expansion

Artivion Inc. reported strong Q2 2026 results, with 9% constant-currency revenue growth driven by stent grafts and On-X mechanical heart valves. The company achieved two major regulatory milestones: FDA PMA approval for the AMDS Hybrid Prosthesis and the completion of the Endospan acquisition following …

Artivion (NYSE:AORT) Delivers Strong Q2 CY2026 Numbers

Artivion (NYSE:AORT) reported strong Q2 CY2026 results, with revenue of $125.8 million, beating analyst estimates by 4.4%, and non-GAAP EPS of $0.13, exceeding estimates by 34.5%. The medical device company reconfirmed its full-year revenue guidance and provided optimistic EBITDA guidance. Despite a decrease in …

Artivion: Q2 Earnings Snapshot

Artivion, Inc. (AORT) reported a second-quarter loss of $13.5 million, or 28 cents per share, which contrasts with a profit in the same period last year. Adjusted earnings for the biological medical device maker were 13 cents per share, with revenue reaching $130.8 million. …

Earnings Flash (AORT) Artivion, Inc. Reports Q2 Revenue $125.8M, vs. FactSet Est of $120.0M

Artivion, Inc. (AORT) has reported its Q2 revenue of $125.8 million, surpassing FactSet's estimate of $120.0 million. This earnings flash indicates a positive financial performance for the medical device company. The news was published on August 6, 2026, at 05:07 pm EDT.

Artivion Reports Second Quarter 2026 Financial Results

Artivion, Inc. announced strong financial results for the second quarter of 2026, with revenue increasing 11% on a GAAP basis and 9% on a constant currency basis. The company reported adjusted EBITDA growth of 7% and highlighted key achievements including the acquisition of Endospan …

Artivion earnings on deck: Can FDA approval revive growth? By Investing.com

Artivion Inc. is set to report its second-quarter earnings, with investors focusing on whether its recent FDA premarket approval for the AMDS Hybrid Prosthesis can counteract slowing sales and revive growth. Despite a 46% drop in shares from their 52-week high and a sequential …

FMR LLC, Abigail Johnson report 4.0% Artivion Inc (AORT) ownership in 13G/A

FMR LLC and Abigail P. Johnson have filed a Schedule 13G/A, reporting a 4.0% beneficial ownership stake in Artivion Inc (AORT). As of June 30, 2026, they collectively beneficially own 1,963,471.40 shares, with FMR LLC holding sole voting power over 1,962,433.00 shares and sole …

Artivion (AORT) Earnings Date and Reports 2026 $AORT

How AMDS Launch Momentum and Capital Discipline Could Reframe Artivion’s (AORT) Growth-Risk Balance

Artivion (AORT), formerly CryoLife, is gaining attention due to the positive physician feedback and early clinical uptake of its AMDS aortic device in the U.S. This new product and focus on capital efficiency could significantly impact the company's growth and operational strategy. The article …

Artivion (AORT) To Report Earnings Tomorrow: Here Is What To Expect

Is Artivion (AORT) Undervalued As Investors Reassess Its Growth And Capital Efficiency?

Artivion (AORT) is being re-evaluated by investors due to its smaller revenue base, limited free cash flow, and capital efficiency challenges. Despite a 14.6% share price increase over the last month, the company has seen a 20.9% decline over 90 days. While some narratives …

Artivion, Inc. Revenue Breakdown – HAM:CYL

Artivion, Inc. (CYL) generated 375.76 million EUR in revenue last year. Its Medical Devices segment was the top performer, contributing 294.44 million EUR. The United States was the primary regional contributor, accounting for 182.27 million EUR of the total revenue.

Artivion Number of Employees 2026 | Employee Count & Headcount Data

Artivion, Inc. (AORT) had 1,828 employees worldwide as of March 2026, representing a 14.8% growth since 2023. The company is actively hiring with 107 job postings in 2026, and its workforce is primarily concentrated in North America (51.1%). The average salary at Artivion is …

Artivion (AORT) Projected to Post Earnings on Thursday

Artivion Inc (AORT) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Artivion Inc (AORT), highlighting its volatility and financial risk. The company's risk assessment score is 8.23, ranking it 23 out of 199 in the Healthcare Equipment & Supplies industry. Key metrics such as beta, VaR, maximum drawdown, …

Artivion's August events include a Boston webcast and virtual meetings

Artivion (NYSE: AORT) announced its participation in two investor conferences in August 2026. Management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12, 2026, with a live webcast available, and will hold investor meetings at the 11th Annual …